Hepatitis B Therapeutics Market Worth $3.5 Billion by 2021

PUNE, India, October 7, 2015 /PRNewswire/ --

The Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth research report published in September 2015 forecasts a 2.3% CAGR to 2021 for the industry.

Spread across 78 pages, talking about 5 marketed products, hepatitis B therapeutic vaccines in pipeline, deals, strategic consolidations and more, complete report on Hepatitis B Therapeutics in Major Developed Markets to 2021 is available at http://www.rnrmarketresearch.com/hepatitis-b-therapeutics-in-major-developed-markets-to-2021-increasing-number-of-migrants-from-high-prevalence-regions-to-drive-market-growth-market-report.html .

The 2015 hepatitis B therapeutic market research states that this rise will occur across the eight major markets of the US, Canada, the UK, France, Germany, Italy, Spain and Japan, and will be primarily driven by increasing immigration from medium and high-prevalence countries. The US, which has one of the largest shares of the HBV treatment market, sees considerable migration from high-prevalence countries, such as the Philippines, China, and Vietnam. While immigration will enlarge the patient pool, HBV treatment market expansion will be restricted by prophylactic vaccination in the US and much of Europe. Increasing use of the premium therapies tenofovir and entecavir will help to drive the market during the forecast period.

Despite this, the global late-stage pipeline is weak due to the lack of first-in-class and innovative products in late-stage clinical development. The products in late-stage development are either mostly generic, biosimilar or an alternative salt formulation, such as GS-7340, which is a different salt formulation of Viread. As a result, apart from GS-7340, which will capture Viread's prescription share, the pipeline products are not going to impact the market by 2021. Furthermore, overall low diagnosis and treatment rates due to the asymptomatic nature of the condition and a lack of awareness, coupled with current drugs serving the market adequately, will hinder further growth. Leading brands treating the condition are also facing competition from generic drugs as major patents approach expiry. The patents of HBV therapeutics expected to expire during the forecast period include Roche's Pegasys, Gilead's Viread and Novartis' Sebivo, says this research.

Marketed products discussed in this hepatitis B therapeutics market report include Viread, Entecavir, Pegasys (peg interferon α-2a), Adefovir dipivoxil and Tyzeka per Sebivo. The therapeutic vaccines in pipeline covered in this research include GS-4774 Therapeutic Vaccine with Oral Antiviral Treatment, ABX203 Therapeutic Vaccine with Nucleos(t)ide Analogs against HBeAg-Negative Chronic Hepatitis B, HB-110E Therapeutic DNA Vaccine, INO-1800 with or without INO-9112 in Entecavir/Tenofovir-Treated HBeAg-Positive Chronic Hepatitis B Patients and TG1050 Therapeutic Vaccine. Order a copy of Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=420215 .

Globally, the hepatitis B therapeutics market is served moderately well by the available products, of which Baraclude and Viread are the most frequently prescribed. However, both have received black-box warnings from the US Food and Drug Administration (FDA), meaning that the market has a high level of unmet need. With 81 active pipeline molecules, most of the investigational drug candidates are small molecules and vaccines, comprising 64% of the pipeline, questions like what are the most prominent small molecules and vaccines in the pipeline? And do the pipeline molecules offer advantages over commercially proven mechanisms? Can be easily answered with the help of this report. Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan as well as discover trends in licensing and co-development deals concerning hepatitis B products and identify the major strategic consolidations that have shaped the commercial landscape through this research.

Explore more reports on the hepatitis drugs market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hepatitis-drugs .

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 

G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research